Cardiac function of long-responders to dual anti-HER2 antibodies amongst patients with HER2 positive advanced breast cancer

被引：0
|
作者：
Bao, Kelvin K. H. [1 ]
Chan, Jeffrey C. H. [1 ]
Sutanto, Leone [1 ]
Chan, Jocelyn G. [1 ]
Cheung, Ka Man [1 ]
Yiu, Harry H. Y. [1 ]
机构：
[1] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1043
引用
收藏
页数：1
相关论文
共 50 条
  • [31] BREAST CANCER BIOMARKERS AND HER2 TESTING AFTER 10 YEARS OF ANTI-HER2 THERAPY
    Ross, Jeffrey S.
    DRUG NEWS & PERSPECTIVES, 2009, 22 (02) : 93 - 106
  • [32] Deregulation of HER2 Downstream Signaling in Breast Cancer Cells by a Cocktail of Anti-HER2 scFvs
    Nejatollahi, Foroogh
    Ranjbar, Reza
    Younesi, Vahid
    Asgharpour, Mahdi
    ONCOLOGY RESEARCH, 2012, 20 (08) : 333 - 340
  • [33] Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients
    Arslan, U. Y.
    Turker, I.
    Aksoy, S.
    Oksuzoglu, B.
    Helvaci, K.
    Ozdemir, N. Yildirim
    Uyeturk, U.
    Sonmez, O. Uysal
    Budakoglu, B.
    Zengin, N.
    JOURNAL OF BUON, 2013, 18 (03): : 585 - 593
  • [34] HER2 status in breast cancer patients: A comparison between borderline positive HER2 and strongly positive HER2 tumors
    Huszno, J.
    Nowara, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S137 - S137
  • [35] Stability of HER2 Expression in Residual Breast Cancer Following Neoadjuvant Anti-HER2 Therapy
    Mir, Mariam O.
    Sahoo, Sunati
    Fang, Yisheng
    Peng, Yan
    Hwang, Helena
    Czapla, Agata
    Koduru, Prasad
    Sarode, Venetia
    LABORATORY INVESTIGATION, 2018, 98 : 91 - 91
  • [36] Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
    Schoellhammer, Hans F.
    Hsu, Felicia
    Vito, Courtney
    Chu, Peiguo
    Park, Jinha
    Waisman, James
    Kim, Joseph
    BMC CANCER, 2014, 14
  • [37] Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
    Hans F Schoellhammer
    Felicia Hsu
    Courtney Vito
    Peiguo Chu
    Jinha Park
    James Waisman
    Joseph Kim
    BMC Cancer, 14
  • [38] Anti-HER2 treatment in advanced metastatic HER2-negative breast cancer patients with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells.
    Kurbacher, Christian M.
    Eichler, Christian A.
    Quade, Annegret Barbara
    Kunstmann, Gerhard
    Herz, Susanne
    Kurbacher, Jutta Anna
    Warm, Mathias R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
    de Azambuja, E.
    Agostinetto, E.
    Procter, M.
    Eiger, D.
    Ponde, N.
    Guillaume, S.
    Parlier, D.
    Lambertini, M.
    Desmet, A.
    Caballero, C.
    Aguila, C.
    Jerusalem, G.
    Walshe, J. M.
    Frank, E.
    Bines, J.
    Loibl, S.
    Piccart-Gebhart, M.
    Ewer, M. S.
    Dent, S.
    Plummer, C.
    Suter, T.
    ESMO OPEN, 2023, 8 (01)
  • [40] Loss of androgen receptor after neoadjuvant anti-HER2 therapy in patients with locally advanced HER2-positive breast cancer
    Espinosa Fernandez, Jose Rodrigo
    Sahin, Aysegul A.
    Hess, Kenneth R.
    Ramirez Medina, Raul Gerardo
    Cabrera Galeana, Paula Anel
    Espana Ferrufino, Alejandro Javier
    Esparza Arias, Nereida
    Bargallo Rocha, Juan Enrique
    Garcia Gordillo, Jose Antonio
    Lopez Muniz, Gerardo Emmanuel
    Ueno, Naoto T.
    CANCER RESEARCH, 2020, 80 (04)
12345